ClinicalTrials.gg
CompletedNCT01380561Updated Oct 18, 2011

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

A Phase 1 interventional study of asimadoline in Healthy, sponsored by Tioga Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years to 56 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-18.

Sponsored by Tioga Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 56 Years
Sex
Male
01

Study summary

This is an open label, single center, metabolite identification, mass balance, and PK study in healthy male volunteers.

Read the detailed description

This is an open label, single center, metabolite identification, mass balance, and PK study in healthy male volunteers. The purposes of this study is to determine the excretion of total [14C] derived radioactivity and the metabolite profile after a single oral dose of [14C] asimadoline as well as to identify and quantitate the metabolites of asimadoline in plasma, urine, and feces after single and multiple oral doses of asimadoline.

02

Conditions studied

  • Healthy

Keywords

  • asimadoline
  • pharmacokinetic
  • excretion of 14C-derived radioactivity
  • metabolite profile
  • 14C-asimadoline
  • metabolites
  • single and multiple oral doses
03

In context

Lead sponsor

Tioga Pharmaceuticals is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 56 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be informed of the nature of the study and have provided written informed voluntary consent
  • Be healthy males, at least 18 years of age or the legal age of consent (whichever is greater) and less than 56 years of age
  • Have a (BMI) >=18.0 and \<32.0 kg/m2 and weigh at least 50 kg
  • Be in good general health with no abnormalities based on the medical history, physical examination, clinical laboratory evaluations (hematology, clinical chemistry, urinalysis), and 12 lead (ECG) that, in the opinion of the Investigator, would affect subject safety
  • Agree to comply with the study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  • Any disease or condition that might affect drug absorption, metabolism, or excretion, or cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease
  • Receipt of a radioisotope with an effective half-life of 30 days or more within the previous 12 months
  • Receipt of any diagnostic radiation procedures with an effective dose exceeding 1 rem in their lifetime
  • Occupational exposure to radiation (e.g., those routinely required to wear a radiation monitoring badge)
  • Receipt of any radiation treatments/therapy
  • History of constipation or infrequent bowel movements (\<=6 bowel movements per week on average)
  • Known or suspected or allergic reaction to asimadoline or similar chemical compounds or any of the components of asimadoline tablets
  • Chronic use of any systemic medications (with the exception of vitamins taken at standard supplement doses); use of a drug therapy (including herbal preparations, e.g., St. John's wort) known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; use of prescription medication within 14 days before administration of study medication or over-the-counter products (including natural products) within 7 days before administration of study medication, except for topical products without systemic absorption, unless approved by the Sponsor
  • Have smoked cigarettes or used nicotine-containing products over the last 3 months and not able to abstain from smoking for the duration of the confinement period
  • If not sterile, cannot agree to use one of the following approved methods of , from check-in until 3 months following Study Completion/Clinic Discharge: a male condom with spermicide; a sterile sexual partner; use by a female sexual partner of an intrauterine device with spermicide; a female condom with spermicide; contraceptive sponge with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives with a reliable secondary back-up method
  • Current history or evidence of drug or alcohol abuse or a positive screen for substances of abuse or alcohol at screening or admission
  • Positive screen for surface antigen (HBsAg), antibody, or (HIV) antibody
  • Receipt of an product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication
  • Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 30 days before administration of study drug
  • Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator, should preclude the subject's participation in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Single Arm Study

    asimadoline

    Drug: asimadoline

Interventions

  • 10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.

    Also known as: EMD 61 753, EMR 63 320

06

What researchers measure

Primary outcomes

  1. Amount of [14C]derived radioactivity in urine and feces after a single oral dose of [14C]asimadoline

    Time frame: up to 1 month

  2. Concentration of metabolites of asimadoline in plasma, urine, and feces after single and multiple oral doses of asimadoline.

    Time frame: up to 1 month

Secondary outcomes

  1. Determination of plasma pharmacokinetics (e.g., Cmax, AUC, tmax, t1/2) of asimadoline and major metabolites

    Time frame: up to 1 month

  2. Number of subjects with adverse events

    Time frame: up to 1 month

07

Study locations

1 site
  • Quintiles Phase 1 Unit
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2011
First posted
Jun 27, 2011
Start
Jun 2011
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Last update
Oct 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01380561
Lead sponsor
Tioga Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Jun 2011
Primary completion
Jul 2011
Completion
Jul 2011
Last update
Oct 18, 2011

Study contacts

Dr. Philip Leese
principal investigator · Quintiles Phase 1 Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asimadoline

Start the discussion